HDAC9 and medulloblastoma: In addition, PI3K/AKT/mTOR signaling is also altered, with preclinical evidence that inhibitors can target medulloblastoma and decrease growth in vitro and in vivo, with synergistic effects combined with HDAC inhibitors [38,39,40].